Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
Subclinical leaflet thrombosis after TAVR | 6 key takeaways from SCCT 2022
Thursday, July 21, 2022
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

Subclinical leaflet thrombosis after TAVR: What we know, and still need to learn, about a challenging complication

Treating subclinical leaflet thrombosis after TAVR has been an ongoing challenge for structural heart clinicians, but recent research has gone a long way toward improving our understanding of this important topic. 

READ MORE >
Subclinical leaflet thrombosis after TAVR imaged by CT. The areas of clot attached to the valve leaflets appear dark. Image courtesy of Cahill et al. and JAMA Cardiology.
Share on Twitter Share on Facebook Share on Linkedin

Subclinical leaflet thrombosis after TAVR: What we know, and still need to learn, about a challenging complication

Share on Twitter Share on Facebook Share on Linkedin
Subclinical leaflet thrombosis after TAVR imaged by CT. The areas of clot attached to the valve leaflets appear dark. Image courtesy of Cahill et al. and JAMA Cardiology.
Treating subclinical leaflet thrombosis after TAVR has been an ongoing challenge for structural heart clinicians, but recent research has gone a long way toward improving our understanding of this important topic. 
READ MORE >

VIDEO: Top 6 takeaways from the Society of Cardiovascular CT 2022 meeting

Eric Williamson, MD, MSCCT, the 2021-2022 president of the Society of Cardiovascular Computed Tomography (SCCT) and professor of radiology at Mayo Clinic, shared his key takeaways from the SCCT 2022 conference. 

READ MORE >
Eric Williamson, MD, MSCCT, the 2021-2022 president of the Society of Cardiovascular Computed Tomography (SCCT) and professor of radiology at Mayo Clinic, shares his key takeaways from the SCCT 2022 conference. #SCCT #SCCT2022 #yesCCT
Share on Twitter Share on Facebook Share on Linkedin

VIDEO: Top 6 takeaways from the Society of Cardiovascular CT 2022 meeting

Share on Twitter Share on Facebook Share on Linkedin
Eric Williamson, MD, MSCCT, the 2021-2022 president of the Society of Cardiovascular Computed Tomography (SCCT) and professor of radiology at Mayo Clinic, shares his key takeaways from the SCCT 2022 conference. #SCCT #SCCT2022 #yesCCT
Eric Williamson, MD, MSCCT, the 2021-2022 president of the Society of Cardiovascular Computed Tomography (SCCT) and professor of radiology at Mayo Clinic, shared his key takeaways from the SCCT 2022 conference. 
READ MORE >

Featured Articles

Restricting salt intake too much may backfire for some heart patients

Limiting salt is a common recommendation for patients hoping to improve their heart health or lose weight. According to a new analysis of more than 1,700 patients, however, going too far with such restrictions can lead to worse outcomes. 

READ MORE >
Salt substitutes are associated with a reduced risk of high blood pressure without increasing the risk of low blood pressure, according to new findings published in the Journal of the American College of Cardiology.[1]
Share on Twitter Share on Facebook Share on Linkedin

Restricting salt intake too much may backfire for some heart patients

Share on Twitter Share on Facebook Share on Linkedin
Salt substitutes are associated with a reduced risk of high blood pressure without increasing the risk of low blood pressure, according to new findings published in the Journal of the American College of Cardiology.[1]
Limiting salt is a common recommendation for patients hoping to improve their heart health or lose weight. According to a new analysis of more than 1,700 patients, however, going too far with such restrictions can lead to worse outcomes. 
READ MORE >

Programmable RNA-DNA anticoagulant fibers may provide a better balance between blood clots and bleeding risks

“We can learn from nature, but we have built something that has never been introduced before,” one researcher said. 

READ MORE >
anticoagulation UNC Charlotte RNA DNA
Share on Twitter Share on Facebook Share on Linkedin

Programmable RNA-DNA anticoagulant fibers may provide a better balance between blood clots and bleeding risks

Share on Twitter Share on Facebook Share on Linkedin
anticoagulation UNC Charlotte RNA DNA
“We can learn from nature, but we have built something that has never been introduced before,” one researcher said. 
READ MORE >

In Other News

Healthcare deals stall in second quarter of 2022

Healthcare deals stalled during the second quarter of 2022, but the baker’s dozen transactions recorded during the three-month period were offset by a high percentage of mega deals.

READ MORE >
stock market
Share on Twitter Share on Facebook Share on Linkedin

Healthcare deals stall in second quarter of 2022

Share on Twitter Share on Facebook Share on Linkedin
stock market
Healthcare deals stalled during the second quarter of 2022, but the baker’s dozen transactions recorded during the three-month period were offset by a high percentage of mega deals.
READ MORE >

Generic CT contrast supplier pledges ‘immediate relief’ from shortage

A global tech and pharma vendor is set to inject U.S. healthcare with a set of generic contrast agents, the first of which will be an FDA-approved substitute for GE Healthcare’s Visipaque.

READ MORE >
A medical professional trained to manage contrast reactions should be on-site at any imaging facilities doing contrast studies to maintain patient safety, according to a an updated statement from the American College of Radiology. The ACR has released the latest edition of the ACR Appropriateness Criteria, which includes 221 diagnostic imaging and interventional radiology topics with more than 1,050 clinical variants covering 2,900 clinical scenarios. #ACR #AUC #appropriateuse
Share on Twitter Share on Facebook Share on Linkedin

Generic CT contrast supplier pledges ‘immediate relief’ from shortage

Share on Twitter Share on Facebook Share on Linkedin
A medical professional trained to manage contrast reactions should be on-site at any imaging facilities doing contrast studies to maintain patient safety, according to a an updated statement from the American College of Radiology. The ACR has released the latest edition of the ACR Appropriateness Criteria, which includes 221 diagnostic imaging and interventional radiology topics with more than 1,050 clinical variants covering 2,900 clinical scenarios. #ACR #AUC #appropriateuse
A global tech and pharma vendor is set to inject U.S. healthcare with a set of generic contrast agents, the first of which will be an FDA-approved substitute for GE Healthcare’s Visipaque.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

TAVR for moderate aortic stenosis | BP drug recalled | Stroke prevention device fails | New Medicare cuts | CCTA-guided PCI
A new way to think about the heart health of women | GLP-1 drugs vs. metformin | Cannabis use may increase risk of CVD, stroke
New Medicare payment cuts | Telemedicine vs. in-person cardiology visits | FDA confirms Class I recall | Startup raises $160M
FDA approves transcatheter treatment for PVL | CCTA-guided PCI | Real-world RDN outcomes | J&J launches new IVL catheter
CCTA vs. IVUS for PCI guidance: Carlos Collet reviews the data | The real-world benefits of RDN | New TAVR tech falls short
TAVR Highlights: New data on treating moderate AS | CMS may expand coverage again | Is surgical backup still necessary?
GLP-1 drugs vs. metformin | BP drug recalled | The health risks of cannabis use | Energy drinks linked to heart issues
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme